FibroScan Service Contract Costs in Australia — and What Clinics Do When the Bill Arrives

The Service Contract Lock-In Model

FibroScan is sold on a standard medical device model: a device purchase, a warranty period, and then an annual service contract to maintain coverage. This is not unusual in medical equipment — but the combination of mandatory service contracts, the additional XL probe for any clinic serving a high-BMI patient population, and the MSAC 1797 rejection (no MBS rebate to offset costs) has made the economics much harder for Australian clinics to justify in 2025.

The service contract covers preventive maintenance, software updates, and parts/labour for repairs. What it does not cover: the XL probe (required for BMI >30 patients), consumables, or operator training for new staff. Clinics report that renewal rates push upward over the device lifetime.

The Hidden Cost: Failed Scans in High-BMI Patients

The service contract is visible and predictable. The failed scan problem is less visible but potentially more costly. In a clinic where 30–40% of patients have BMI >30 — entirely typical for an Australian MAFLD practice — the M probe's 20–25% failure rate in that cohort means 1 in 4 of those patients leaves without a usable result. That patient visit generated zero clinical value and needs to be rescheduled (if they return) or referred elsewhere.

If a clinic performs 200 MAFLD-indicated scans per year, with 40% in BMI >30, that is 80 high-BMI scans — at 20% failure, 16 failed scans per year. At $150 per scan, that is $2,400 in unrecoverable revenue, plus the clinical cost of unresolved patient pathways. Over 3 years: approximately $7,200 in failed scans on top of service contract costs.